Somatropin oral - Emisphere Technologies

Drug Profile

Somatropin oral - Emisphere Technologies

Alternative Names: Oral recombinant human growth hormone - Emisphere Technologies/Novartis; rhGH - Emisphere Technologies/Novartis

Latest Information Update: 04 May 2012

Price : $50

At a glance

  • Originator Emisphere Technologies
  • Developer Emisphere Technologies; Novartis
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Growth disorders

Most Recent Events

  • 16 Jul 2013 Biomarkers information updated
  • 13 Aug 2011 Novartis terminates its licence for oral somatropin
  • 13 Aug 2011 Discontinued - Phase-I for Growth disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top